LIVER CANCER NEWS TIPS & FEATURES


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Checkpoint Inhibitor News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.
Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer

February 15, 2018

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer

By Anonymous User anonymous_user_10987

CancerConnect News:  According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About Liver Cancer Liver cancer, or hepatocellular carcinoma (HCC), is the second most common cause of cancer-related deaths worldwide.2,3 […]

View full entry

Tags: checkpoint inhibitor, hepatocellular cancer, immunotherapy, keytruda, Liver Cancer, News Tips and Features, News Tips and Features Other, pembrolizumab, Precision Cancer Medicine


Keytruda Promising in PD-L1 Esophageal Cancer

February 13, 2018

Keytruda Promising in PD-L1 Esophageal Cancer

By Anonymous User anonymous_user_10987

CancerConnect News: The checkpoint inhibitor Keytruda (pembrolizumab) has been reported to produce an overall response rate of 30% in patients with PD-L1–positive, advanced esophageal cancer.1 About Keytruda Keytruda is a monoclonal antibody that helps to restore the body’s immune system in fighting cancer. It creates its anti-cancer effects by blocking a specific protein used by cancer […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, gastroesophageal junction cancer, immunotherapy, keytruda, News Tips and Features, News Tips and Features Other, pembrolizumab, Precision Cancer Medicine


The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer

September 25, 2017

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer

By Anonymous User anonymous_user_10987

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors, and must demonstrate disease progression after two or more prior lines of therapy – including fluoropyrimidine- and platinum-containing chemotherapy and, in some cases, HER2/neu-targeted […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, Gastric Cancer, gastro-esophogeal junction cancer, keytruda, metastatic gastric, News Tips and Features, News Tips and Features Other, pembrolizumab, Precision Cancer Medicine


View more articles like this
More news and in-depth Esophageal Cancer information

CONDITIONS OF THE GI TRACT